FDA: Avoid Cipro, Similar Drugs for Common Infections — Agency says risks outweigh benefits


05.12.2016 INFECTIOUS DISEASE
WASHINGTON
Fluoroquinolone antibiotics, the class that includes ciprofloxacin (Cipro), ciprofloxacin, getifloxacin, ofloxacin, pefloxacin, sparfloxacin, levofloxacin , e.t.c
should not be used to treat uncomplicated infections such as sinusitis, bronchitis, and urinary tract infections for which other drug types are effective, the FDA announced Thursday.
Only patients with these conditions who can't be treated with other agents should receive fluoroquinolones, the agency said.
"An FDA safety review has shown that fluoroquinolones when used systemically (i.e., tablets, capsules, and injectable) are associated with disabling and potentially permanent serious side effects that can occur together. These side effects can involve the tendons, muscles, joints, nerves, and central nervous system," the FDA said.
Labels and medication guides for these agents will be updated to reflect the review's findings
.
The FDA noted that it has had concerns about fluoroquinolones for these uses for many years, having included boxed warnings about the tendon risks in 2008, for example.

Last year, the agency convened an advisory committee meeting to review the risk-benefit balance for fluoroquinolones. The panel agreed that the balance was unfavorable for sinusitis, bronchitis, and other common conditions for which multiple treatment options exist.

Comments

Post a Comment

Cool

Popular posts from this blog

10 EARLY PREGNANCY SYMPTOMS WHICH APPEAR BEFORE MISSING A PERIOD

Many women experience the first pregnancy symptoms days before missing a period as a result of the shift in the hormones, which causes certain changes in the body. The first pregnancy symptoms can occur up to a week before a sufficient number of pregnancy hormones starts to circulate in the body to give a positive result on the pregnancy test. Here are the earliest symptoms of pregnancy, which appear before a missed period. Pregnancy Symptoms Cramping Cramping is one of the earliest symptoms of pregnancy. The cramps can be noticed when your embryo implants into your uterus. This sign can be easily mistaken for menstrual cramps. Fatigue Increased levels of progesterone can make you feel exhausted. Fatigue is usually experienced as early as a week after ovulation. After you ovulate, the levels of progesterone rise, regardless of being pregnant or not. However, if you are not pregnant your progesterone levels will soon decrease. After ovulation, if you start feeling tired, and if t...
Read more

First Birth Control For Men, An Injection To The Groin, Will Be Available Soon

The use of contraceptives has been largely associated with women, but birth control for men might soon be available for use after Indian scientists announced that they have successfully completed clinical trials on the world’s first male birth control injection. The Indian Council for Medical Research said that the “product is ready,” and has a 97.3% success rate with no side effects, according to a report from the Hindustan Times. The contraceptive works via an injection to the vas deferens, the sperm-containing tube near the testicles. It contains a polymer called Steryene Maleic Anhydride, which was developed in the 1970s to inhibit sperm production. According to the report, the contraceptive will be effective for 13 years. VG Somani, the Drug Controller General of India, estimates approval of the drug to take around six months, minimum. “It’s the first in the world from India so we have to be extra careful about approval. We are looking at all aspects, especiall...
Read more

Novartis sickle-cell drug gets U.S. FDA approval

By John Miller and Carl O’Donnell (Reuters) - Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. The drug will be priced between $84,852 and $113,136 per year for most patients, who will be infused by a healthcare provider with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. The Food and Drug Administration’s approval came nearly two months ahead of its due date for a decision in January. Novartis has forecast that the drug’s annual sales will top $1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid. The dru...
Read more